59,400 Shares in Edwards Lifesciences Corporation $EW Acquired by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 59,400 shares of the medical research company’s stock, valued at approximately $5,373,000.

Other large investors also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $803,686,000. Conway Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $954,000. TD Asset Management Inc grew its holdings in shares of Edwards Lifesciences by 6.4% during the 4th quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock worth $66,335,000 after purchasing an additional 47,051 shares during the period. Intech Investment Management LLC raised its holdings in Edwards Lifesciences by 22.2% in the fourth quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock valued at $5,912,000 after buying an additional 12,591 shares during the period. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Edwards Lifesciences during the fourth quarter valued at approximately $1,626,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 2.4%

Shares of EW opened at $90.02 on Friday. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The stock has a 50-day moving average price of $89.12 and a 200 day moving average price of $84.63. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The company has a market capitalization of $51.83 billion, a P/E ratio of 51.74, a P/E/G ratio of 2.32 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the business earned $0.67 EPS. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on EW. UBS Group began coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price objective for the company. Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Truist Financial increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Finally, Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.